|
Real-time Estimate
Cboe Europe
04:38:53 2026-09-02 EDT
|
5-day change | 1st Jan Change | ||
| 129.96 CHF | -0.76% |
|
+2.26% | +18.67% |
| 09-01 | Health Care Up on Defensive Bias - Health Care Roundup | DJ |
| 09-01 | Swiss Market Index Recovers; Novartis Gains Amid Positive Late-stage Multiple Sclerosis Drug Data | MT |
Company Valuation: Novartis AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 196,458 | 194,448 | 207,167 | 195,514 | 266,003 | 306,772 | - | - |
| Change | - | -1.02% | 6.54% | -5.62% | 36.05% | 15.33% | - | - |
| Enterprise Value (EV) 1 | 204,649 | 203,482 | 219,178 | 213,458 | 289,870 | 339,451 | 334,589 | 327,645 |
| Change | - | -0.57% | 7.71% | -2.61% | 35.8% | 17.1% | -1.43% | -2.08% |
| P/E | 8.2x | 28.3x | 14.1x | 16.5x | 19.2x | 22.9x | 19.5x | 17x |
| PBR | 2.9x | 3.23x | 4.41x | 4.52x | 5.73x | 6.45x | 6.02x | 5.41x |
| PEG | - | -0.4x | 0x | -1x | 0.9x | -9.99x | 1.1x | 1.2x |
| Capitalization / Revenue | 3.81x | 3.85x | 4.44x | 3.78x | 4.69x | 5.32x | 5x | 4.71x |
| EV / Revenue | 3.96x | 4.03x | 4.7x | 4.13x | 5.11x | 5.89x | 5.46x | 5.03x |
| EV / EBITDA | 11.2x | 10.9x | 12.2x | 10.2x | 12.4x | 14.6x | 13.3x | 12x |
| EV / EBIT | 12.3x | 12.2x | 13.4x | 10.9x | 13.2x | 15.6x | 14.1x | 12.8x |
| EV / FCF | 15.4x | 17x | 16.6x | 13.1x | 16.5x | 22.1x | 19.8x | 16.9x |
| FCF Yield | 6.49% | 5.87% | 6.01% | 7.61% | 6.07% | 4.53% | 5.05% | 5.91% |
| Dividend per Share 2 | 3.36 | 3.5 | 3.823 | 3.856 | - | 4.371 | 4.559 | 4.741 |
| Rate of return | 3.83% | 3.87% | 3.79% | 3.94% | - | 2.71% | 2.82% | 2.94% |
| EPS 2 | 10.71 | 3.19 | 7.15 | 5.92 | 7.21 | 7.045 | 8.281 | 9.485 |
| Distribution rate | 31.4% | 110% | 53.5% | 65.1% | - | 62% | 55.1% | 50% |
| Net sales 1 | 51,626 | 50,545 | 46,660 | 51,722 | 56,674 | 57,649 | 61,309 | 65,194 |
| EBITDA 1 | 18,246 | 18,613 | 17,937 | 21,006 | 23,415 | 23,251 | 25,200 | 27,207 |
| EBIT 1 | 16,588 | 16,665 | 16,372 | 19,494 | 21,889 | 21,800 | 23,654 | 25,653 |
| Net income 1 | 24,021 | 6,955 | 14,854 | 11,939 | 13,967 | 13,951 | 15,502 | 17,368 |
| Net Debt 1 | 8,191 | 9,034 | 12,011 | 17,944 | 23,867 | 32,680 | 27,818 | 20,873 |
| Reference price 2 | 87.82 | 90.40 | 100.79 | 97.79 | 138.63 | 161.40 | 161.40 | 161.40 |
| Nbr of stocks (in thousands) | 2,237,092 | 2,150,980 | 2,055,460 | 1,999,270 | 1,918,792 | 1,900,715 | - | - |
| Announcement Date | 2/2/22 | 2/1/23 | 1/31/24 | 1/31/25 | 2/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 22.91x | 5.89x | 14.6x | 2.71% | 307B | |
| 33.02x | 11.99x | 24.3x | 0.6% | 1,034B | |
| 29.7x | - | - | 1.98% | 654B | |
| 33.18x | 7.69x | 15.99x | 2.64% | 459B | |
| 19.36x | 4.61x | 11.42x | 2.88% | 343B | |
| 20.82x | 4.27x | 12.21x | 2.06% | 251B | |
| 27.71x | 7.15x | 12.7x | 2.3% | 237B | |
| 13.18x | 4.74x | 9.88x | 3.82% | 202B | |
| -45.81x | 6.6x | 25.78x | 2.2% | 186B | |
| 17.89x | 3.38x | 8.62x | 6.03% | 163B | |
| Average | 17.20x | 6.26x | 15.06x | 2.72% | 383.43B | |
| Weighted average by Cap. | 23.81x | 7.80x | 17.33x | 2.13% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- NOVN Stock
- Valuation Novartis AG
Select your edition
All financial news and data tailored to specific country editions
